Regulus Therapeutics Inc. announced the completion of enrollment in the Phase 2 HERA clinical study evaluating lademirsen for the treatment of adult patients with Alport Syndrome under the Company's Collaboration and License Agreement with Sanofi. Lademirsen is a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of miR-21. Initiated in September 2017, the HERA study is a global, randomized, placebo-controlled Phase 2 study designed to assess the safety and tolerability of lademirsen, as well as the efficacy in reducing the decline in renal function in adult patients with Alport Syndrome.

The Company expects HERA results in the first half of 2023. In 2020, Regulus achieved $10 million in milestone payments associated with the completion of transfer and verification of certain materials as well as an interim enrollment milestone from Sanofi for its progress with the HERA study. Under the terms of the Collaboration and License Agreement, the Company is also eligible to receive an additional $25 million upon successful completion of the ongoing HERA study.